@rheumnow #ACR19 ABS2353 Real-life observ cohort study demonstrates ACPA testing well adopted by US rheum (77.6% tested at Dx) but does not influence treatment choice (Rx w/bDMARD had similar distribution regardless of ACPA status) https://t.co/2V8VqHATJd